Chang Yi Wang
Co-founder of UBI, Chairperson of the Board of Directors since 1998, and Chairperson and CEO of UBI-Asia. Dr. Wang is the principal inventor of over 80 of UBI’s issued patents and patent applications. Under her direction, the UBITh platform technology was developed. She has published more than 120 peer reviewed scientific papers and has been invited to give plenary lectures in the areas of immunology, vaccination, immunotherapeutics and infectious diseases. She also serves on the US NIH scientific review committee for the “Cooperative Research Partnerships for BioDefense” funding program and the SBIR Immunobiology and Allergy funding program.  In 2007 Dr. Wang received the Inventor of the Year Award from the New York Intellectual Property Law Association (NYPLA). From 1981 to 1985, Dr. Wang was a principal investigator and head of the Laboratory of Molecular Immunology at the Memorial Sloan-Kettering Cancer Center in New York and a faculty member of the Department of Immunology, Sloan-Kettering Division, Cornell University Medical School. Dr. Wang received her B.S. degree in Chemistry from National Taiwan University and her Ph.D. degree in Immunology and Biochemistry from The Rockefeller University, New York.

Nean Hu
Co-founder and President of UBI-China. Mr. Hu’s establishment and management of operations in China, through funds raised in China, has allowed for the manufacturing and marketing of UBI blood screening tests to worldwide markets and the license approval of UBI’s FMD swine vaccine as a first class new biologics by Ministry of Agriculture of the People’s Republic of China.  Prior to the founding of UBI, he was President of Dafa Industries, Inc., an electromechanical manufacturing company.  Mr. Hu received his B.S. degree in Physics from Shanghai Institute of Science and Technology, China.

Joop Sistemans
Member of the Board of Directors since 1999, filling the position held for the previous 6½ years by Dr. James Watson, the Nobel laureate and co-discoverer of the structure for DNA, who retired from the Board at age 70.  Currently, Mr. Sistemans is the Chairman of the Advisory Council for Science and Technology Policy to the Prime Minister, the Netherlands.  He was the CEO of Origin B.V., an information technology company in the Netherlands from 1999 to 2001.  From 1994 to 1999, Mr. Sistermans served as the Executive Vice President of Akzo Nobel responsible for Strategy & Technology.  He was President and CEO of Organon Teknika and member of the Board of the Pharma Division of Akzo Nobel from 1989 until he became Executive VP at its then parent Akzo Nobel in 1994.

Flossie Wong-Staal
Dr. Wong-Staal is a Professor of Medicine and Biology and has held the Florence Riford Chair in AIDS Research at the University of California, San Diego (UCSD) since 1990.  Dr. Wong-Staal is an internationally recognized leader in virology and one of the pioneers of AIDS research.  While at the National Cancer Institute (NCI), she and her colleagues were the first to decipher the complex structure of HIV, Dr. Wong-Staal serves on the National Task Force on AIDS Drug Development, the Health Policy Board of the Institute of Medicine, the Science Board for the Food and Drug Administration and the Board of Scientific Counselors for the National Institute of Allergy and Infectious Diseases.  She has been elected as a member of the Institute of Medicine, the Academia Sinica, and as an honorary member of the American Society of Clinical Investigation.

Lefan Gong
Dr. LeFan Gong received his S.J.D., LL.M. from the University of Michigan Law School, his LL.M. from Fudan University Law School, and his LL.B. from Zhejiang University Law School.  His area of practice includes Capital Markets, M&A, PE/VC, FDI, anti-monopoly/ competition, Overseas Investment, New Energy and Natural Resources, Media and Entertainment, Food and Medication.  He represents large multinational and U.S. Fortune 500 companies and large Chinese enterprises in cross-border mergers and acquisitions, joint ventures, real estate investment, corporate restructuring and other international investment, international trade and commercial transactions, including technology development and licensing.  He has been a keynote speaker at various meetings, including china Green Business Summit of China Society for Environmental Sciences, and most recently, at the In-House Congress event in Hong Kong where his presentation, “Setting up RMB Funds – Obstacles, Models and Trends” focused on how foreign sponsors may set up private equity and real estate funds in  China, the legal and regulatory framework and available structure options and red flags for risk management in fund formation in China.